News
-
-
PRESS RELEASE
Ondine Biomedical Inc Announces ECDC Report Shows Rising HAIs and Antibiotic Use
ECDC report reveals rise in antibiotic-resistant HAIs, emphasizing Ondine Biomedical's light-activated antimicrobial technology. The technology offers a solution to combat antimicrobial resistance by killing all types of pathogens without causing resistance -
-
-
-
PRESS RELEASE
Ondine Biomedical Inc Announces Corporate and Trading Update
Ondine Biomedical (LON:OBI) reports significant revenue growth and commercial momentum in 2023 with doubled revenues and increased number of hospital deployments, including strategic inroads in the UK, Spain, and Australia. The company also announces distribution partnerships and plans for US Phase 3 Clinical Trial -
-
-
-
PRESS RELEASE
Ondine Biomedical Inc. Announces 32% Fewer SSIs After Steriwave Replaced Mupirocin
Study at Mazankowski Alberta Heart Institute shows 32% reduction in cardiac infections with Steriwave replacing antibiotic standard. Significant cost savings and high compliance. Expert commentary available
-
Revolutionizing Fire Camps: NUE's Sustainable Power Solutions Shine at USDA Technology & Development Center
-
Save A Train Continues to Innovate with Rail Enrichment
-
Cameron Ashley Building Products Opens Third Location in the Badger State
-
Event Tickets Center is Named Official Secondary Ticketing Reseller Partner for Most Valuable Promotions and the Historic Jake Paul vs. Mike Tyson Fight
-
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
-
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
-
secunet Security Networks AG successfully holds Annual General Meeting – Broad approval for all proposed resolutions
-
TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Fuller, Smith & Turner PLC: Transaction in own shares
-
AngloGold Ashanti US$9.0m (A$13.5m) Gold Farm-in Agreement
-
2024 Annual General Meeting: approval of all resolutions submitted to the Meeting
-
PR – ICADE – Success of the cash tender offer for a total amount of €350 million
-
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
-
Availability of preparatory documents for the annual general meeting of June 13, 2024
-
Safran’s 2024 Annual General Meeting